Revolution Medicines
RVMD
284 hedge funds and large institutions have $6.83B invested in Revolution Medicines in 2025 Q1 according to their latest regulatory filings, with 48 funds opening new positions, 98 increasing their positions, 88 reducing their positions, and 41 closing their positions.
17% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 41
11% more repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 88
1% more funds holding
Funds holding: 281 → 284 (+3)
2.34% less ownership
Funds ownership: 105.87% → 103.52% (-2.3%)
9% less funds holding in top 10
Funds holding in top 10: 23 → 21 (-2)
19% less capital invested
Capital invested by funds: $8.45B → $6.83B (-$1.62B)
71% less call options, than puts
Call options by funds: $7.19M | Put options by funds: $25.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$67.9M |
| 2 |
Westfield Capital Management
Boston,
Massachusetts
|
+$43M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$39.2M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$32.5M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$32.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Boxer Capital Management
San Diego,
California
|
-$120M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$65.4M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$57M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$53.5M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$19.7M |
RVMD Hedge Fund Activity: Q1 2025 in Review
284 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Revolution Medicines (RVMD) for Q1 2025, worth a combined $6.83B — down 19% from $8.45B a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new RVMD positions and 41 closed out — a net gain of 7 holders — while 98 added to existing stakes and 88 trimmed.
The largest buyer was T. Rowe Price Investment Management, opening a new position worth an estimated $67.9M. The largest seller was Boxer Capital Management, cutting an estimated $120M.
- 284 institutional investors held Revolution Medicines (RVMD) as of Q1 2025, up from 281 in Q4 2024.
- Funds reported $6.83B of Revolution Medicines stock for Q1 2025, down 19% quarter-over-quarter.
- 48 funds opened new Revolution Medicines positions in Q1 2025 and 41 closed out, a net change of +7 holders.
- The largest Revolution Medicines buyer in Q1 2025 was T. Rowe Price Investment Management, an estimated $67.9M added.
- The largest Revolution Medicines seller in Q1 2025 was Boxer Capital Management, an estimated $120M sold.
Based on aggregated 13F filings for Q1 2025.